From Wikipedia, the free encyclopedia
Hypertension is a chronic medical condition in which the blood pressure is elevated. It is also referred to as high blood pressure or shortened to HT, HTN or HPN. The word "hypertension", by itself, normally refers to systemic, arterial hypertension.
Hypertension can be classified as either essential (primary) or secondary. Essential or primary hypertension means that no medical cause can be found to explain the raised blood pressure and represents about 90-95% of hypertension cases. Secondary hypertension indicates that the high blood pressure is a result of (i.e., secondary to) another condition, such as kidney disease or tumours (adrenal adenoma or pheochromocytoma).
Persistent hypertension is one of the risk factors for strokes, heart attacks, heart failure and arterial aneurysm, and is a leading cause of chronic renal failure. Even moderate elevation of arterial blood pressure leads to shortened life expectancy. At severely high pressures, defined as mean arterial pressures 50% or more above average, a person can expect to live no more than a few years unless appropriately treated. Beginning at a systolic pressure (which is peak pressure in the arteries, which occurs near the end of the cardiac cycle when the ventricles are contracting) of 115 mmHg and diastolic pressure (which is minimum pressure in the arteries, which occurs near the beginning of the cardiac cycle when the ventricles are filled with blood) of 75 mmHg (commonly written as 115/75 mmHg), cardiovascular disease (CVD) risk doubles for each increment of 20/10 mmHg.
The variation in pressure in the left ventricle
(blue line) and the aorta
(red line) over two cardiac cycles
("heart beats"), showing the definitions of systolic and diastolic pressure.
A recent classification recommends blood pressure criteria for defining normal blood pressure, prehypertension, hypertension (stages I and II), and isolated systolic hypertension, which is a common occurrence among the elderly. These readings are based on the average of seated blood pressure readings that were properly measured during 2 or more office visits. In individuals older than 50 years, hypertension is considered to be present when a person's blood pressure is consistently at least 140 mmHg systolic or 90 mmHg diastolic. Patients with blood pressures over 130/80 mmHg along with Type 1 or Type 2 diabetes, or kidney disease require further treatment.
|Source: American Heart Association (2003).
Resistant hypertension is defined as the failure to reduce blood pressure to the appropriate level after taking a three-drug regimen (include thiazide diuretic). Guidelines for treating resistant hypertension have been published in the UK, and US.
Excessive elevation in blood pressure during exercise is called exercise hypertension. The upper normal systolic values during exercise reach levels between 200 and 230 mm Hg. Exercise hypertension may be regarded as a precursor to established hypertension at rest.
Signs and symptoms
Mild to moderate essential hypertension is usually asymptomatic. Accelerated hypertension is associated with headache, somnolence, confusion, visual disturbances, and nausea and vomiting (hypertensive encephalopathy). Retinas are affected with narrowing of arterial diameter to less than 50% of venous diameter, copper or silver wire appearance, exudates, hemorrhages, or papilledema. Some signs and symptoms are especially important in infants and neonates such as failure to thrive, seizure, irritability or lethargy, and respiratory distress. While in children hypertension may cause headache, fatigue, blurred vision, epistaxis, and bell palsy.
Some signs and symptoms are especially important in suggesting a secondary medical cause of chronic hypertension, such as centripetal obesity, "buffalo hump," and/or wide purple abdominal striae and maybe a recent onset of diabetes suggest glucocorticoid excess either due to Cushing's syndrome or other causes. Hypertension due to other secondary endocrine diseases such as hyperthyroidism, hypothyroidism, or growth hormone excess show symptoms specific to these disease such as in hyperthyrodism there may be weight loss, tremor, tachycardia or atrial arrhythmia, palmar erythema and sweating. Signs and symptoms associated with growth hormone excess such as coarsening of facial features, prognathism, macroglossia, hypertrichosis, hyperpigmentation, and hyperhidrosis may occur in these patients.:499. Other endocrine causes such as hyperaldosteronism may cause less specific symptoms such as numbness, polyuria, polydipsia, hypernatraemia, and metabolic alkalosis. A systolic bruit heard over the abdomen or in the flanks suggests renal artery stenosis. Also radio femoral delay or diminished pulses in lower versus upper extremities suggests coarctation of the aorta. Hypertension in patients with pheochromocytomas is usually sustained but may be episodic. The typical attack lasts from minutes to hours and is associated with headache, anxiety, palpitation, profuse perspiration, pallor, tremor, and nausea and vomiting. Blood pressure is markedly elevated, and angina or acute pulmonary edema may occur. In primary aldosteronism, patients may have muscular weakness, polyuria, and nocturia due to hypokalemia. Chronic hypertension often leads to left ventricular hypertrophy, which can present with exertional and paroxysmal nocturnal dyspnea. Cerebral involvement causes stroke due to thrombosis or hemorrhage from microaneurysms of small penetrating intracranial arteries. Hypertensive encephalopathy is probably caused by acute capillary congestion and exudation with cerebral edema, which is reversible.
Signs and symptoms associated with pre-eclampsia and eclampsia, can be proteinuria, edema, and hallmark of eclampsia which is convulsions, Other cerebral signs may precede the convulsion such as nausea, vomiting, headaches, and blindness.
While one of the most common disorders, essential hypertension, by definition idiopathic, has an unknown cause . It is the most prevalent hypertension type, affecting 90-95% of hypertensive patients. Although no direct cause has identified itself, there are many factors such as sedentary lifestyle, Stress, visceral obesity, potassium deficiency (hypokalemia)  obesity (more than 85% of cases occur in those with a body mass index greater than 25), salt (sodium) sensitivity, alcohol intake, and vitamin D deficiency. Risk also increases with aging, some inherited genetic mutations and family history. An elevation of Renin, an enzyme secreted by the kidney, is another risk factor, as is sympathetic nervous system overactivity. Insulin resistance which is a component of syndrome X, or the metabolic syndrome is also thought to contribute to hypertension. Recent studies have implicated low birth weight as a risk factor for adult essential hypertension.
Secondary hypertension by definition results from an identifiable cause. This type is important to recognize since it's treated differently than essential type by treating the underlying cause.
Many secondary causes can cause hypertension, some are common and well recognized secondary causes such as Cushing's syndrome, which is a condition where both adrenal glands can overproduce the hormone cortisol. Hypertension results from the interplay of several pathophysiological mechanisms regulating plasma volume, peripheral vascular resistance and cardiac output, all of which may be increased. More than 80% of patients with Cushing's syndrome have hypertension. Another important cause is the congenital abnormality coarctation of the aorta.
A variety of adrenal cortical abnormalities can cause hypertension, In primary aldosteronism there is a clear relationship between the aldosterone-induced sodium retention and the hypertension. Another related disorder that causes hypertension is apparent mineralocorticoid excess syndrome which is an autosomal recessive disorder results from mutations in gene encoding 11β-hydroxysteroid dehydrogenase which normal patient inactivates circulating cortisol to the less-active metabolite cortisone. Cortisol at high concentrations can cross-react and activate the mineralocorticoid receptor, leading to aldosterone-like effects in the kidney, causing hypertension. This effect can also be produced by prolonged ingestion of liquorice(which can be of potent strength in liquorice candy), can result in inhibition of the 11β-hydroxysteroid dehydrogenase enzyme and cause secondary apparent mineralocorticoid excess syndrome. Frequently, if liquorice is the cause of the high blood pressure, a low blood level of potassium will also be present. Yet another related disorder causing hypertension is glucocorticoid remediable aldosteronism, which is an autosomal dominant disorder in which the increase in aldosterone secretion produced by ACTH is no longer transient, causing of primary hyperaldosteronism, the Gene mutated will result in an aldosterone synthase that is ACTH-sensitive, which is normally not. GRA appears to be the most common monogenic form of human hypertension. Compare these effects to those seen in Conn's disease, an adrenocortical tumor which causes excess release of aldosterone, that leads to hypertension.
Another adrenal related cause is Cushing's syndrome which is a disorder caused by high levels of cortisol. Cortisol is a hormone secreted by the cortex of the adrenal glands. Cushing's syndrome can be caused by taking glucocorticoid drugs, or by tumors that produce cortisol or adrenocorticotropic hormone (ACTH). More than 80% of patients with Cushing's syndrome develop hypertension., which is accompanied by distinct symptoms of the syndrome, such as central obesity, buffalo hump, moon face, sweating, hirsutism and anxiety.
Other well known causes include diseases of the kidney. This includes diseases such as polycystic kidney disease which is a cystic genetic disorder of the kidneys, PKD is characterized by the presence of multiple cysts (hence, "polycystic") in both kidneys, can also damage the liver, pancreas, and rarely, the heart and brain. It can be autosomal dominant or autosomal recessive, with the autosomal dominant form being more common and characterized by progressive cyst development and bilaterally enlarged kidneys with multiple cysts, with concurrent development of hypertension, renal insufficiency and renal pain. Or chronic glomerulonephritis which is a disease characterized by inflammation of the glomeruli, or small blood vessels in the kidneys. Hypertension can also be produced by diseases of the renal arteries supplying the kidney. This is known as renovascular hypertension; it is thought that decreased perfusion of renal tissue due to stenosis of a main or branch renal artery activates the renin-angiotensin system. also some renal tumors can cause hypertension. The differential diagnosis of a renal tumor in a young patient with hypertension includes Juxtaglomerular cell tumor, Wilms' tumor, and renal cell carcinoma, all of which may produce renin.
Neuroendocrine tumors are also a well known cause of secondary hypertension. Pheochromocytoma (most often located in the adrenal medulla) increases secretion of catecholamines such as epinephrine and norepinephrine, causing excessive stimulation of adrenergic receptors, which results in peripheral vasoconstriction and cardiac stimulation. This diagnosis is confirmed by demonstrating increased urinary excretion of epinephrine and norepinephrine and/or their metabolites (vanillylmandelic acid).
Medication side effects
Certain medications, especially NSAIDs (Motrin/Ibuprofen) and steroids can cause hypertension. High blood pressure that is associated with the sudden withdrawal of various antihypertensive medications is called rebound hypertension. The increases in blood pressure may result in blood pressures greater than when the medication was initiated. Depending on the severity of the increase in blood pressure, rebound hypertension may result in a hypertensive emergency. Rebound hypertension is avoided by gradually reducing the dose (also known as "dose tapering"), thereby giving the body enough time to adjust to reduction in dose. Medications commonly associated with rebound hypertension include centrally-acting antihypertensive agents, such as clonidine and beta-blockers.
Few women of childbearing age have high blood pressure, up to 11% develop hypertension of pregnancy. While generally benign, it may herald three complications of pregnancy: pre-eclampsia, HELLP syndrome and eclampsia. Follow-up and control with medication is therefore often necessary.
Another common and under-recognized sign of hypertension is sleep apnea, which is often best treated with nocturnal nasal continuous positive airway pressure (CPAP), but other approaches include the Mandibular advancement splint (MAS), UPPP, tonsillectomy, adenoidectomy, septoplasty, or weight loss. Another cause is an exceptionally rare neurological disease called Binswanger's disease, causing dementia; it is a rare form of multi-infarct dementia, and is one of the neurological syndromes associated with hypertension.
Because of the ubiquity of arsenic in ground water supplies and its effect on cardiovascular health, low dose arsenic poisoning should be inferred as a part of the pathogenesis of idiopathic hypertension. Idiopathic and essential are both somewhat synonymous with primary hypertension. Arsenic exposure has also many of the same signs of primary hypertension such as headache, somnolence,  confusion, proteinuria  visual disturbances, and nausea and vomiting 
Due to the role of intracellular potassium in regulation of cellular pressures related to sodium, establishing potassium balance has been show to reverse hypertension. 
Most of the mechanisms associated with secondary hypertension are generally fully understood. However, those associated with essential (primary) hypertension are far less understood. What is known is that cardiac output is raised early in the disease course, with total peripheral resistance (TPR) normal; over time cardiac output drops to normal levels but TPR is increased. Three theories have been proposed to explain this:
It is also known that hypertension is highly heritable and polygenic (caused by more than one gene) and a few candidate genes have been postulated in the etiology of this condition.
Recently, work related to the association between essential hypertension and sustained endothelial damage has gained popularity among hypertension scientists. It remains unclear however whether endothelial changes precede the development of hypertension or whether such changes are mainly due to long standing elevated blood pressures.
Initial assessment of the hypertensive patient should include a complete history and physical examination to confirm a diagnosis of hypertension. Most patients with hypertension have no specific symptoms referable to their blood pressure elevation. Although popularly considered a symptom of elevated arterial pressure, headache generally occurs only in patients with severe hypertension. Characteristically, a "hypertensive headache" occurs in the morning and is localized to the occipital region. Other nonspecific symptoms that may be related to elevated blood pressure include dizziness, palpitations, easy fatiguability, and impotence.
Measuring blood pressure
Main article: Blood pressure
Diagnosis of hypertension is generally on the basis of a persistently high blood pressure. Usually this requires three separate measurements at least one week apart. Exceptionally, if the elevation is extreme, or end-organ damage is present then the diagnosis may be applied and treatment commenced immediately.
Obtaining reliable blood pressure measurements relies on following several rules and understanding the many factors that influence blood pressure reading.
For instance, measurements in control of hypertension should be at least 1 hour after caffeine, 30 minutes after smoking or strenuous exercise and without any stress. Cuff size is also important. The bladder should encircle and cover two-thirds of the length of the (upper) arm. The patient should be sitting upright in a chair with both feet flat on the floor for a minimum of five minutes prior to taking a reading. The patient should not be on any adrenergic stimulants, such as those found in many cold medications.
When taking manual measurements, the person taking the measurement should be careful to inflate the cuff suitably above anticipated systolic pressure. The person should inflate the cuff to 200 mmHg and then slowly release the air while palpating the radial pulse. After one minute, the cuff should be reinflated to 30 mmHg higher than the pressure at which the radial pulse was no longer palpable. A stethoscope should be placed lightly over the brachial artery. The cuff should be at the level of the heart and the cuff should be deflated at a rate of 2 to 3 mmHg/s. Systolic pressure is the pressure reading at the onset of the sounds described by Korotkoff (Phase one). Diastolic pressure is then recorded as the pressure at which the sounds disappear (K5) or sometimes the K4 point, where the sound is abruptly muffled. Two measurements should be made at least 5 minutes apart, and, if there is a discrepancy of more than 5 mmHg, a third reading should be done. The readings should then be averaged. An initial measurement should include both arms. In elderly patients who particularly when treated may show orthostatic hypotension, measuring lying sitting and standing BP may be useful. The BP should at some time have been measured in each arm, and the higher pressure arm preferred for subsequent measurements.
BP varies with time of day, as may the effectiveness of treatment, and archetypes used to record the data should include the time taken. Analysis of this is rare at present.
Automated machines are commonly used and reduce the variability in manually collected readings. Routine measurements done in medical offices of patients with known hypertension may incorrectly diagnose 20% of patients with uncontrolled hypertension.
Home blood pressure monitoring can provide a measurement of a person's blood pressure at different times throughout the day and in different environments, such as at home and at work. Home monitoring may assist in the diagnosis of high or low blood pressure. It may also be used to monitor the effects of medication or lifestyle changes taken to lower or regulate blood pressure levels. Home monitoring of blood pressure can also assist in the diagnosis of white coat hypertension. The American Heart Association states, "You may have what's called 'white coat hypertension'; that means your blood pressure goes up when you're at the doctor's office. Monitoring at home will help you measure your true blood pressure and can provide your doctor with a log of blood pressure measurements over time. This is helpful in diagnosing and preventing potential health problems."
Some home blood pressure monitoring devices also make use of blood pressure charting software. These charting methods provide printouts for the patient's physician and reminders to take a blood pressure reading. However, a simple and cheap way is simply to manually record values with pen and paper, which can then be inspected by a doctor.
Systolic hypertension is defined as an elevated systolic blood pressure. If systolic blood pressure is elevated with a normal diastolic blood pressure, it is called isolated systolic hypertension. Systolic hypertension may be due to reduced compliance of the aorta with increasing age.
Once the diagnosis of hypertension has been made it is important to attempt to exclude or identify reversible (secondary) causes. Secondary hypertension is more common in preadolescent children, with most cases caused by renal disease. Primary or essential hypertension is more common in adolescents and has multiple risk factors, including obesity and a family history of hypertension. Tests are undertaken to identify possible causes of secondary hypertension, and seek evidence for end-organ damage to the heart itself or the eyes (retina) and kidneys. Diabetes and raised cholesterol levels being additional risk factors for the development of cardiovascular disease are also tested for as they will also require management. Tests done are classified as follows:
||Microscopic urinalysis, proteinuria, serum BUN (blood urea nitrogen) and/or creatinine
||Serum sodium, potassium, calcium, TSH (thyroid-stimulating hormone).
||Fasting blood glucose, total cholesterol, HDL and LDL cholesterol, triglycerides
||Hematocrit, electrocardiogram, and Chest X-ray
|Sources: Harrison's principles of internal medicine others
Creatinine (renal function) testing is done to identify both the underlying renal disease as a cause of hypertension and, conversely, hypertension causing the onset of kidney damage. It is a baseline for monitoring the possible side-effects of certain antihypertensive drugs later. Glucose testing is done to identify diabetes mellitus. Additionally, testing of urine samples for proteinuria detection is used to pick up an underlying kidney disease or evidence of hypertensive renal damage. Electrocardiogram (EKG/ECG) testing is done to check for evidence of the heart being under strain from working against a high blood pressure. It may also show a resulting thickening of the heart muscle (left ventricular hypertrophy) or of the occurrence of a previously silent cardiac disease (either a subtle electrical conduction disruption or even a myocardial infarction). A chest X-ray might be used to observe signs of cardiac enlargement or evidence of cardiac failure.
The degree to which hypertension can be prevented depends on a number of features including: current blood pressure level, sodium/potassium balance, detection and omission of environmental toxins, changes in end/target organs (retina, kidney, heart - among others), risk factors for cardiovascular diseases and the age at presentation. Unless the presenting patient has very severe hypertension, there should be a relatively prolonged assessment period within which repeated measurements of blood pressure should be taken. Following this, lifestyle advice and non-pharmacological options should be offered to the patient, before any initiation of drug therapy.
The process of managing hypertension according the guidelines of the British Hypertension Society suggest that non-pharmacological options should be explored in all patients who are hypertensive or pre-hypertensive. These measures include;
- Weight reduction and regular aerobic exercise (e.g., walking) are recommended as the first steps in treating mild to moderate hypertension. Regular exercise improves blood flow and helps to reduce resting heart rate and blood pressure. Several studies indicate that low intensity exercise may be more effective in lowering blood pressure than higher intensity exercise. These steps are highly effective in reducing blood pressure, although drug therapy is still necessary for many patients with moderate or severe hypertension to bring their blood pressure down to a safe level.
- Reducing dietary sugar intake.
- Reducing sodium (salt) in the diet may be effective: It decreases blood pressure in about 33% of people (see above). Many people use a salt substitute to reduce their salt intake.
- Additional dietary changes beneficial to reducing blood pressure include the DASH diet (dietary approaches to stop hypertension) which is rich in fruits and vegetables and low-fat or fat-free dairy foods. This diet has been shown to be effective based on research sponsored by the National Heart, Lung, and Blood Institute. In addition, an increase in dietary potassium, which offsets the effect of sodium has been shown to be highly effective in reducing blood pressure.
- Discontinuing tobacco use and alcohol consumption has been shown to lower blood pressure. The exact mechanisms are not fully understood, but blood pressure (especially systolic) always transiently increases following alcohol or nicotine consumption. Besides, abstention from cigarette smoking is important for people with hypertension because it reduces the risk of many dangerous outcomes of hypertension, such as stroke and heart attack. Note that coffee drinking (caffeine ingestion) also increases blood pressure transiently but does not produce chronic hypertension.
- Reducing stress, for example with relaxation therapy, such as meditation and other mindbody relaxation techniques, by reducing environmental stress such as high sound levels and over-illumination can be an additional method of ameliorating hypertension. Jacobson's Progressive Muscle Relaxation and biofeedback are also used, particularly, device-guided paced breathing, although meta-analysis suggests it is not effective unless combined with other relaxation techniques.
Lifestyle changes such as the DASH diet, physical exercise, and weight loss have been shown to significantly reduced blood pressure in people with high blood pressure. If hypertension is high enough to justify immediate use of medications, lifestyle changes are initiated concomitantly.
A series of UK guidelines advocate treatment initiation thresholds and desirable targets to be reached as set out in the following table. Of particular note is that for patients with blood pressures between 140-159/80-99 and without additional factors, that only lifestyle actions and regular blood pressure and risk-factor review is proposed.
Biofeedback devices can be used alone or in conjunction with lifestyle changes or medications to monitor and possibly reduce hypertension. One example is Resperate, a portable, battery-operated personal therapeutic medical device, sold over the counter (OTC) in the United States. However, claims of efficacy are not supported by scientific studies. Testimonials are used to promote such products, while no real evidence exists that the use of resperate like devices lowers any morbidity associated with hypertension.
There are many classes of medications for treating hypertension, together called antihypertensives, which — by varying means — act by lowering blood pressure. Evidence suggests that reduction of the blood pressure by 5–6 mmHg can decrease the risk of stroke by 40%, of coronary heart disease by 15–20%, and reduces the likelihood of dementia, heart failure, and mortality from vascular disease.
The aim of treatment should be blood pressure control to <140/90 mmHg for most patients, and lower in certain contexts such as diabetes or kidney disease (some medical professionals recommend keeping levels below 120/80 mmHg). Each added drug may reduce the systolic blood pressure by 5–10 mmHg, so often multiple drugs are often necessary to achieve blood pressure control.
Commonly used drugs include the typical groups of:
- ACE inhibitors such as captopril, enalapril, fosinopril (Monopril), lisinopril (Zestril), quinapril, ramipril (Altace)
- Angiotensin II receptor antagonists may be used where ACE inhibitors are not tolerated: eg, telmisartan (Micardis, Pritor), irbesartan (Avapro), losartan (Cozaar), valsartan (Diovan), candesartan (Amias), olmesartan (Benicar, Olmetec)
- Calcium channel blockers such as nifedipine (Adalat) amlodipine (Norvasc), diltiazem, verapamil
- Diuretics: eg, bendroflumethiazide, chlorthalidone, hydrochlorothiazide (also called HCTZ).
Other additionally used groups include:
Finally several agents may be given simultaneously:
- Combination products (which usually contain HCTZ and one other drug). The advantage of fixed combinations resides in the fact that they increase compliance with treatment by reducing the number of pills taken by the patients. A fixed combination of the ACE inhibitor perindopril and the calcium channel blocker amlodipine, recently been proved to be very effective even in patients with additional impaired glucose tolerance and in patients with the metabolic syndrome.
Choice of initial medication
For mild blood pressure elevation, consensus guidelines call for medically-supervised lifestyle changes and observation before recommending initiation of drug therapy. However, according to the American Hypertension Association, evidence of sustained damage to the body may be present even prior to observed elevation of blood pressure. Therefore the use of hypertensive medications may be started in individuals with apparent normal blood pressures but who show evidence of hypertension related nephropathy, proteinuria, atherosclerotic vascular disease, as well as other other evidence of hypertension related organ damage.
If lifestyle changes are ineffective, then drug therapy is initiated, often requiring more than one agent to effectively lower hypertension. Which type of many medications should be used initially for hypertension has been the subject of several large studies and various national guidelines.
The largest study, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), concluded that thiazide-type diuretics are better and cheaper than other major classes of drugs at preventing cardiovascular disease, and should be preferred as the starting drug. ALLHAT used the thiazide diuretic chlorthalidone. (ALLHAT showed that doxazosin, an alpha-adrenergic receptor blocker, had a higher incidence of heart failure events, and the doxazosin arm of the study was stopped.)
A subsequent smaller study (ANBP2) did not show the slight advantages in thiazide diuretic outcomes observed in the ALLHAT study, and actually showed slightly better outcomes for ACE-inhibitors in older white male patients.
Thiazide diuretics are effective, recommended as the best first-line drug for hypertension by many experts, and are much more affordable than other therapies, yet they are not prescribed as often as some newer drugs. Hydrochlorothiazide is perhaps the safest and most inexpensive agent commonly used in this class and is very frequently combined with other agents in a single pill. Doses in excess of 25 milligrams per day of this agent incur an unacceptable risk of low potassium or Hypokalemia. Patients with an exaggerated hypokalemic response to a low dose of a thiazide diuretic should be suspected to have Hyperaldosteronism, a common cause of secondary hypertension.
Other drugs have a role in treating hypertension. Adverse effects of thiazide diuretics include hypercholesterolemia, and impaired glucose tolerance with increased risk of developing Diabetes mellitus type 2. The thiazide diuretics also deplete circulating potassium unless combined with a potassium-sparing diuretic or supplemental potassium. Some authors have challenged thiazides as first line treatment. However as the Merck Manual of Geriatrics notes, "thiazide-type diuretics are especially safe and effective in the elderly."
Current UK guidelines suggest starting patients over the age of 55 years and all those of African/Afrocaribbean ethnicity firstly on calcium channel blockers or thiazide diuretics, whilst younger patients of other ethnic groups should be started on ACE-inhibitors. Subsequently if dual therapy is required to use ACE-inhibitor in combination with either a calcium channel blocker or a (thiazide) diuretic. Triple therapy is then of all three groups and should the need arise then to add in a fourth agent, to consider either a further diuretic (e.g. spironolactone or furosemide), an alpha-blocker or a beta-blocker. Prior to the demotion of beta-blockers as first line agents, the UK sequence of combination therapy used the first letter of the drug classes and was known as the "ABCD rule".
Diagram illustrating the main complications of persistent high blood pressure.
It is based upon several factors including genetics, dietary habits, and overall lifestyle choices. If individuals conscious of their condition take the necessary preventive measures to lower their blood pressure, they are more likely to have a much better outcome than those who do not.
Hypertension is a risk factor for all clinical manifestations of atherosclerosis since it is a risk factor for atherosclerosis itself. It is an independent predisposing factor for heart failure, coronary artery disease, stroke, renal disease, and peripheral arterial disease. it is the most important risk factor for cardiovascular morbidity and mortality in industrialized countries. The risk is increased for:
Graph showing, prevalence of awareness, treatment and control of hypertension compared between the four studies of NHANES
It is estimated that nearly one billion people are affected by hypertension worldwide, and this figure is predicted to increase to 1.5 billion by 2025. The level of blood pressure regarded as deleterious has been revised down during years of epidemiological studies. A widely quoted and important series of such studies is the Framingham Heart Study carried out in an American town: Framingham, Massachusetts. The results from Framingham and of similar work in Busselton, Western Australia have been widely applied. To the extent that people are similar this seems reasonable, but there are known to be genetic variations in the most effective drugs for particular sub-populations. Recently (2004), the Framingham figures have been found to overestimate risks for the UK population considerably. The reasons are unclear. Nevertheless the Framingham work has been an important element of UK health policy.
Over 90-95% of adult hypertension is of the essential hypertension type. It is estimated that 43 million people in the United States have hypertension or are taking antihypertensive medication, which is almost 24% of the adult population. This proportion changes with race, being higher in blacks and lower in whites and Mexican Americans ; second it changes with age, because in industrialized countries systolic BP rises throughout life, whereas diastolic BP rises until age 55 to 60 years and thus the greater increase in prevalence of hypertension among the elderly is mainly due to systolic hypertension; also geographic patterns, because hypertension is more prevalent in the southeastern United States; another important one is gender, because hypertension is more prevalent in men (though menopause tends to abolish this difference); and finally socioeconomic status, which is an indicator of lifestyle attributes and is inversely related to the prevalence, morbidity, and mortality rates of hypertension. A series of studies and surveys conducted by National Health and Nutrition Examination Survey (NHANES) between 1976 and 2004 to assess the trends in hypertension prevalence, blood pressure distributions and mean levels, and hypertension awareness, treatment, and control among US adults, aged more than 18 years, showed that there is an increasing pattern of awareness, control and treatment of hypertension, and that prevalence of hypertension is increasing reaching 28.9% as of 2004, with the largest increases among non-Hispanic women.
For the secondary hypertension its known that primary aldosteronism is the most frequent endocrine form of secondary hypertension. The incidence of exercise hypertension is reported to range from 1 to 10% of the total population.
Hypertension often is part of the metabolic "syndrome X" its co-occurring with other components of the syndrome. The other components are, diabetes mellitus, combined hyperlipidemia, and central obesity. This is especially occurring among women. And this co-occurrence will increase the risk of cardiovascular disease and cardiovascular events.
Children and adolescents
As with adults, blood pressure is a variable parameter in children. It varies between individuals and within individuals from day to day and at various times of the day. And the population prevalence of high blood pressure in the young is increasing. The epidemic of childhood obesity, the risk of developing left ventricular hypertrophy, and evidence of the early development of atherosclerosis in children would make the detection of and intervention in childhood hypertension important to reduce long-term health risks. Most childhood hypertension, particularly in preadolescents, is secondary to an underlying disorder. Renal parenchymal disease is the most common (60 to 70%) cause of hypertension. Adolescents usually have primary or essential hypertension, making up 85 to 95% of cases.. Medical students commonly suffer from hypertension especially mature students.
Some cite the writings of Sushruta in the 6th century BC as being the first mention of symptoms like those of hypertension.
Our modern understanding of hypertension began with the work of physician William Harvey (1578–1657). It was then recognized as a disease a century later by Richard Bright (physician) in (1789–1858). The first ever elevated blood pressure in a patient without kidney disease was reported by Frederick Mahomed (1849–1884).
Society and culture
The National Heart, Lung, and Blood Institute (NHLBI) estimated in 2002 that hypertension cost the United States $47.2 billion dollars.
High blood pressure is the most common chronic medical problem prompting visits to primary health care providers, yet it is estimated that only 34% of the 50 million American adults with hypertension have their blood pressure controlled to a level of <140/90 mm Hg. Thus, about two thirds of Americans with hypertension are at increased risk for cardiovascular events. The medical, economic, and human costs of untreated and inadequately controlled high blood pressure are enormous. Adequate management of hypertension can be hampered by inadequacies in the diagnosis, treatment, and/or control of high blood pressure. Health care providers face many obstacles to achieving blood pressure control among their patients, including a limited ability to adequately lower blood pressure with monotherapy and a typical reluctance to increase therapy (either in dose or number of medications) to achieve blood pressure goals. Patients also face important challenges in adhering to multidrug regimens and accepting the need for therapeutic lifestyle changes. Nonetheless, the achievement of blood pressure goals is possible, and, most importantly, lowering blood pressure significantly reduces cardiovascular morbidity and mortality, as proved in clinical trials. The medical and human costs of treating preventable conditions such as stroke, heart failure, and end-stage renal disease can be reduced by antihypertensive treatment. The recurrent and chronic morbidities associated with hypertension are costly to treat. Pharmacotherapy for hypertension therefore offers a substantial potential for cost savings. Recent studies proved that the use of angiotensin receptor blockers for treatment of hypertension is cost-saving and cost-effective treatment compared with other conventional treatment.
The World Health Organization attributes hypertension, or high blood pressure, as the leading cause of cardiovascular mortality. The World Hypertension League (WHL), an umbrella organization of 85 national hypertension societies and leagues, recognized that more than 50% of the hypertensive population worldwide are unaware of their condition. To address this problem, the WHL initiated a global awareness campaign on hypertension in 2005 and dedicated May 17 of each year as World Hypertension Day (WHD). Over the past three years, more national societies have been engaging in WHD and have been innovative in their activities to get the message to the public. In 2007, there was record participation from 47 member countries of the WHL. During the week of WHD, all these countries – in partnership with their local governments, professional societies, nongovernmental organizations and private industries – promoted hypertension awareness among the public through several media and public rallies. Using mass media such as Internet and television, the message reached more than 250 million people. As the momentum picks up year after year, the WHL is confident that almost all the estimated 1.5 billion people affected by elevated blood pressure can be reached.
- ^ Maton, Anthea; Jean Hopkins, Charles William McLaughlin, Susan Johnson, Maryanna Quon Warner, David LaHart, Jill D. Wright (1993). Human Biology and Health. Englewood Cliffs, New Jersey, USA: Prentice Hall. ISBN 0-13-981176-1. OCLC 32308337.
- ^ a b c d e Carretero OA, Oparil S (January 2000). "Essential hypertension. Part I: definition and etiology". Circulation 101 (3): 329–35. PMID 10645931. http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=10645931. Retrieved 2009-06-05.
- ^ a b c Oparil S, Zaman MA, Calhoun DA (November 2003). "Pathogenesis of hypertension". Ann. Intern. Med. 139 (9): 761–76. PMID 14597461.
- ^ a b c Hall, John E.; Guyton, Arthur C. (2006). Textbook of medical physiology. St. Louis, Mo: Elsevier Saunders. p. 228. ISBN 0-7216-0240-1.
- ^ a b c "Hypertension: eMedicine Nephrology". http://emedicine.medscape.com/article/241381-overview. Retrieved 2009-06-05.
- ^ Pierdomenico SD, Di Nicola M, Esposito AL, et al. (June 2009). "Prognostic Value of Different Indices of Blood Pressure Variability in Hypertensive Patients". American Journal of Hypertension 22 (8): 842–7. doi:10.1038/ajh.2009.103. PMID 19498342.
- ^ Guyton & Hall (2005). Textbook of Medical Physiology (7th ed.). Elsevier-Saunders. p. 220. ISBN 0-7216-0240-1. OCLC 213041516.
- ^ a b c d Chobanian AV, Bakris GL, Black HR, et al. (December 2003). "Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure". Hypertension 42 (6): 1206–52. doi:10.1161/01.HYP.0000107251.49515.c2. PMID 14656957. http://hyper.ahajournals.org/cgi/content/full/42/6/1206.
- ^ a b c d e f "CG34 Hypertension - quick reference guide" (PDF). National Institute for Health and Clinical Excellence. 28 June 2006. http://www.nice.org.uk/nicemedia/pdf/cg034quickrefguide.pdf. Retrieved 2009-03-04.
- ^ Calhoun DA, Jones D, Textor S, et al. (June 2008). "Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research" (PDF). Hypertension 51 (6): 1403–19. doi:10.1161/HYPERTENSIONAHA.108.189141. PMID 18391085. http://hyper.ahajournals.org/cgi/reprint/51/6/1403.pdf.
- ^ Jetté M, Landry F, Blümchen G (April 1987). "Exercise hypertension in healthy normotensive subjects. Implications, evaluation and interpretation". Herz 12 (2): 110–8. PMID 3583204.
- ^ Pickering TG (April 1987). "Pathophysiology of exercise hypertension". Herz 12 (2): 119–24. PMID 2953661.
- ^ a b Rost R, Heck H (April 1987). "[Exercise hypertension--significance from the viewpoint of sports]" (in German). Herz 12 (2): 125–33. PMID 3583205.
- ^ a b c Klaus D (April 1987). "[Differential therapy of exercise hypertension]" (in German). Herz 12 (2): 146–55. PMID 3583208.
- ^ Pitts SR, Adams RP (February 1998). "Emergency department hypertension and regression to the mean". Annals of Emergency Medicine 31 (2): 214–8. doi:10.1016/S0196-0644(98)70309-9. PMID 9472183.
- ^ Chiang WK, Jamshahi B (November 1998). "Asymptomatic hypertension in the ED". The American Journal of Emergency Medicine 16 (7): 701–4. doi:10.1016/S0735-6757(98)90181-4. PMID 9827753.
- ^ Decker WW, Godwin SA, Hess EP, Lenamond CC, Jagoda AS (March 2006). "Clinical policy: critical issues in the evaluation and management of adult patients with asymptomatic hypertension in the emergency department". Annals of Emergency Medicine 47 (3): 237–49. doi:10.1016/j.annemergmed.2005.10.003. PMID 16492490. http://linkinghub.elsevier.com/retrieve/pii/S0196-0644(05)01790-7. Retrieved 2009-06-18.
- ^ Rogers RL, Anderson RS (May 2007). "Severe hypertension in the geriatric patient-is it an emergency or not?". Clinics in Geriatric Medicine 23 (2): 363–70, vii. doi:10.1016/j.cger.2007.01.008. PMID 17462522. http://journals.elsevierhealth.com/retrieve/pii/S0749-0690(07)00009-2. Retrieved 2009-06-18.
- ^ Zeller KR, Von Kuhnert L, Matthews C (October 1989). "Rapid reduction of severe asymptomatic hypertension. A prospective, controlled trial". Archives of Internal Medicine 149 (10): 2186–9. doi:10.1001/archinte.149.10.2186. PMID 2679473. http://archinte.ama-assn.org/cgi/pmidlookup?view=long&pmid=2679473. Retrieved 2009-06-18.
- ^ a b Papadakis, Maxine A.; McPhee, Stephen J. (2008). Current Medical Diagnosis and Treatment 2009 (Current Medical Diagnosis and Treatment). McGraw-Hill Professional. ISBN 0-07-159124-9.
- ^ a b c "Hypertension: eMedicine Pediatrics: Cardiac Disease and Critical Care Medicine". http://emedicine.medscape.com/article/889877-overview. Retrieved 2009-06-16.
- ^ "Hyperthyroidism: eMedicine Endocrinology". http://emedicine.medscape.com/article/121865-overview. Retrieved 2009-06-16.
- ^ "Acromegaly: eMedicine Endocrinology". http://emedicine.medscape.com/article/116366-overview. Retrieved 2009-06-16.
- ^ James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin: Clinical Dermatology. (10th ed.). Saunders. ISBN 0721629210.
- ^ "Hyperaldosteronism: eMedicine Pediatrics: General Medicine". http://emedicine.medscape.com/article/920713-overview. Retrieved 2009-06-16.
- ^ "Hypertension and Pregnancy: eMedicine Obstetrics and Gynecology". http://emedicine.medscape.com/article/261435-overview. Retrieved 2009-06-16.
- ^ name="pmid17148735">Kyrou I, Chrousos GP, Tsigos C (November 2006). [http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0077-8923&date=2006&volume=1083&spage=77 "
- ^ Hypertension. 2006;48:201.)© 2006 American Heart Association, Inc. Editorial Commentaries Potassium Depletion and Diastolic Dysfunction David B. Young From the Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Miss.and metabolic complications"]. Ann. N. Y. Acad. Sci. 1083: 77–110. doi:10.1196/annals.1367.008. PMID 17148735. http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0077-8923&date=2006&volume=1083&spage=77. Retrieved 2009-06-01.
- ^ Wofford MR, Hall JE (2004). "Pathophysiology and treatment of obesity hypertension". Curr. Pharm. Des. 10 (29): 3621–37. doi:10.2174/1381612043382855. PMID 15579059. http://www.bentham-direct.org/pages/content.php?CPD/2004/00000010/00000029/0007B.SGM. Retrieved 2009-06-07.
- ^ a b c Segura J, Ruilope LM (October 2007). "Obesity, essential hypertension and renin-angiotensin system". Public Health Nutr 10 (10A): 1151–5. doi:10.1017/S136898000700064X. PMID 17903324. http://journals.cambridge.org/abstract_S136898000700064X. Retrieved 2009-06-01.
- ^ a b Uchiyama M (August 2008). "[Mild hypertension in children]" (in Japanese). Nippon Rinsho 66 (8): 1477–80. PMID 18700545.
- ^ a b Rahmouni K, Correia ML, Haynes WG, Mark AL (January 2005). "Obesity-associated hypertension: new insights into mechanisms". Hypertension 45 (1): 9–14. doi:10.1161/01.HYP.0000151325.83008.b4. PMID 15583075.
- ^ a b Haslam DW, James WP (2005). "Obesity". Lancet 366 (9492): 1197–209. doi:10.1016/S0140-6736(05)67483-1. PMID 16198769.
- ^ Lackland DT, Egan BM (August 2007). "Dietary salt restriction and blood pressure in clinical trials". Curr. Hypertens. Rep. 9 (4): 314–9. doi:10.1007/s11906-007-0057-8. PMID 17686383.
- ^ Rodriguez-Iturbe B, Romero F, Johnson RJ (October 2007). "Pathophysiological mechanisms of salt-dependent hypertension". Am. J. Kidney Dis. 50 (4): 655–72. doi:10.1053/j.ajkd.2007.05.025. PMID 17900467. http://linkinghub.elsevier.com/retrieve/pii/S0272-6386(07)00945-6. Retrieved 2009-06-01.
- ^ http://www.jstage.jst.go.jp/article/jphs/100/5/370/_pdf A Missing Link Between a High Salt Intake and Blood Pressure Increase: Makoto Katori and Masataka Majima, Department of Pharmacology, Kitasato University School of Medicine, Kitasato, Sagamihara, Kanagawa, Japan February 8, 2006
- ^ Jürgens G, Graudal NA (2004). "Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride". Cochrane Database Syst Rev (1): CD004022. doi:10.1002/14651858.CD004022.pub2. PMID 14974053.
- ^ Djoussé L, Mukamal KJ (June 2009). "Alcohol Consumption and Risk of Hypertension: Does the Type of Beverage or Drinking Pattern Matter?". Rev Esp Cardiol 62 (6): 603–605. doi:10.1016/S1885-5857(09)72223-6. PMID 19480755. http://www.revespcardiol.org/cgi-bin/wdbcgi.exe/cardio/mrevista_cardio.pubmed_full?inctrl=05ZI0113&vol=62&num=6&pag=603. Retrieved 2009-06-03.
- ^ Weber, Michael (2001). Hypertension medicine. Totowa, N.J: Humana. ISBN 0-89603-788-6.
- ^ Tuohimaa P (March 2009). "Vitamin D and aging". The Journal of Steroid Biochemistry and Molecular Biology 114 (1-2): 78–84. doi:10.1016/j.jsbmb.2008.12.020. PMID 19444937.
- ^ Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF (2008). "Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor?". J. Am. Coll. Cardiol. 52 (24): 1949–56. doi:10.1016/j.jacc.2008.08.050. PMID 19055985.
- ^ Forman JP, Giovannucci E, Holmes MD, et al. (May 2007). "Plasma 25-hydroxyvitamin D levels and risk of incident hypertension". Hypertension 49 (5): 1063–9. doi:10.1161/HYPERTENSIONAHA.107.087288. PMID 17372031.
- ^ Kosugi T, Nakagawa T, Kamath D, Johnson RJ (February 2009). "Uric acid and hypertension: an age-related relationship?". J Hum Hypertens 23 (2): 75–6. doi:10.1038/jhh.2008.110. PMID 18754017.
- ^ Cite error: Invalid
<ref> tag; no text was provided for refs named
pmid16754793; see Help:Cite error.
- ^ Gong M, Hubner N (March 2006). "Molecular genetics of human hypertension". Clin. Sci. 110 (3): 315–26. doi:10.1042/CS20050208. PMID 16464173. http://www.clinsci.org/cs/110/0315/cs1100315.htm. Retrieved 2009-06-01.
- ^ Qiu CC, Zhou WY (April 2006). "[Susceptible genes of essential hypertension]" (in Chinese). Zhongguo Yi Xue Ke Xue Yuan Xue Bao 28 (2): 284–8. PMID 16733921.
- ^ Harrison M, Maresso K, Broeckel U (December 2008). "Genetic determinants of hypertension: an update". Curr. Hypertens. Rep. 10 (6): 488–95. doi:10.1007/s11906-008-0091-1. PMID 18959837.
- ^ Kotchen TA, Kotchen JM, Grim CE, et al. (July 2000). "Genetic determinants of hypertension: identification of candidate phenotypes". Hypertension 36 (1): 7–13. PMID 10904005. http://hyper.ahajournals.org/cgi/pmidlookup?view=long&pmid=10904005.
- ^ "Hypertension Etiology & Classification - Secondary Hypertension". Armenian Medical Network. 2006. http://www.health.am/hypertension/secondary-hypertension/. Retrieved 2007-12-02.
- ^ a b Luma GB, Spiotta RT (May 2006). "Hypertension in children and adolescents". Am Fam Physician 73 (9): 1558–68. PMID 16719248.
- ^ a b Loscalzo, Joseph; Fauci, Anthony S.; Braunwald, Eugene; Dennis L. Kasper; Hauser, Stephen L; Longo, Dan L. (2008). Harrison's principles of internal medicine. McGraw-Hill Medical. ISBN 0-07-147691-1.
- ^ Inaba S, Iwai M, Horiuchi M (August 2008). "[Role of RAS in prehypertension]" (in Japanese). Nippon Rinsho 66 (8): 1503–8. PMID 18700549.
- ^ a b c Sorof J, Daniels S (October 2002). "Obesity hypertension in children: a problem of epidemic proportions". Hypertension 40 (4): 441–7. doi:10.1161/01.HYP.0000032940.33466.12. PMID 12364344. http://hyper.ahajournals.org/cgi/pmidlookup?view=long&pmid=12364344. Retrieved 2009-06-03.
- ^ Esler M, Rumantir M, Kaye D, Lambert G (June 2001). "The sympathetic neurobiology of essential hypertension: disparate influences of obesity, stress, and noradrenaline transporter dysfunction?". Am. J. Hypertens. 14 (6 Pt 2): 139S–146S. doi:10.1016/S0895-7061(01)02081-7. PMID 11411749.
- ^ Esler M, Rumantir M, Kaye D, et al. (December 2001). "Sympathetic nerve biology in essential hypertension". Clin. Exp. Pharmacol. Physiol. 28 (12): 986–9. doi:10.1046/j.1440-1681.2001.03566.x. PMID 11903299. http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0305-1870&date=2001&volume=28&issue=12&spage=986. Retrieved 2009-06-01.
- ^ Esler M, Alvarenga M, Pier C, et al. (July 2006). "The neuronal noradrenaline transporter, anxiety and cardiovascular disease". J. Psychopharmacol. (Oxford) 20 (4 Suppl): 60–6. doi:10.1177/1359786806066055. PMID 16785272. http://jop.sagepub.com/cgi/pmidlookup?view=long&pmid=16785272. Retrieved 2009-06-01.
- ^ Reaven GM (December 2005). "Insulin resistance, the insulin resistance syndrome, and cardiovascular disease". Panminerva Med 47 (4): 201–10. PMID 16489319.
- ^ Bagby SP (April 2007). "Maternal nutrition, low nephron number, and hypertension in later life: pathways of nutritional programming". J. Nutr. 137 (4): 1066–72. PMID 17374679. http://jn.nutrition.org/cgi/pmidlookup?view=long&pmid=17374679. Retrieved 2009-06-01.
- ^ a b c Dodt C, Wellhöner JP, Schütt M, Sayk F (January 2009). "[Glucocorticoids and hypertension]" (in German). Der Internist 50 (1): 36–41. doi:10.1007/s00108-008-2197-6. PMID 19096817.
- ^ a b Giacchetti G, Turchi F, Boscaro M, Ronconi V (April 2009). "Management of primary aldosteronism: its complications and their outcomes after treatment". Current Vascular Pharmacology 7 (2): 244–49. doi:10.2174/157016109787455716. PMID 19356005. http://www.bentham-direct.org/pages/content.php?CVP/2009/00000007/00000002/014AD.SGM. Retrieved 2009-06-19.
- ^ Bailey MA, Paterson JM, Hadoke PW, et al. (January 2008). "A switch in the mechanism of hypertension in the syndrome of apparent mineralocorticoid excess". Journal of the American Society of Nephrology : JASN 19 (1): 47–58. doi:10.1681/ASN.2007040401. PMID 18032795. PMC 2391031. http://jasn.asnjournals.org/cgi/pmidlookup?view=long&pmid=18032795. Retrieved 2009-06-19.
- ^ Vantyghem MC, Marcelli-Tourvieille S, Defrance F, Wemeau JL (October 2007). "[11beta-hydroxysteroide dehydrogenases. Recent advances"] (in French). Annales D'endocrinologie 68 (5): 349–56. doi:10.1016/j.ando.2007.02.003 (inactive 2009-10-19). PMID 17368420. http://www.masson.fr/masson/S0003-4266(07)00039-X. Retrieved 2009-06-19.
- ^ Atanasov AG, Ignatova ID, Nashev LG, et al. (April 2007). "Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess". Journal of the American Society of Nephrology : JASN 18 (4): 1262–70. doi:10.1681/ASN.2006111235. PMID 17314322. http://jasn.asnjournals.org/cgi/pmidlookup?view=long&pmid=17314322. Retrieved 2009-06-19.
- ^ a b Johns C (January 2009). "Glycyrrhizic acid toxicity caused by consumption of licorice candy cigars". CJEM : Canadian Journal of Emergency Medical Care = JCMU : Journal Canadien De Soins Médicaux D'urgence 11 (1): 94–6. PMID 19166646. http://caep.ca/template.asp?id=41e4ddc5c30c4ceebd15a779632204b5. Retrieved 2009-06-19.
- ^ Sontia B, Mooney J, Gaudet L, Touyz RM (February 2008). "Pseudohyperaldosteronism, liquorice, and hypertension". J Clin Hypertens (Greenwich) 10 (2): 153–7. doi:10.1111/j.1751-7176.2008.07470.x. PMID 18256580. http://www.lejacq.com/articleDetail.cfm?pid=JClinHypertens_10;2:153.
- ^ Escher G (April 2009). "Hyperaldosteronism in pregnancy". Therapeutic Advances in Cardiovascular Disease 3 (2): 123–32. doi:10.1177/1753944708100180. PMID 19171690. http://tak.sagepub.com/cgi/pmidlookup?view=long&pmid=19171690. Retrieved 2009-06-19.
- ^ Sukor N, Mulatero P, Gordon RD, et al. (August 2008). "Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families". Journal of Hypertension 26 (8): 1577–82. doi:10.1097/HJH.0b013e3283028352. PMID 18622235. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0263-6352&volume=26&issue=8&spage=1577. Retrieved 2009-06-19.
- ^ Omura M, Nishikawa T (May 2006). "[Glucocorticoid remediable aldosteronism]" (in Japanese). Nippon Rinsho. Japanese Journal of Clinical Medicine Suppl 1: 628–34. PMID 16776234.
- ^ Luft FC (October 2003). "Mendelian forms of human hypertension and mechanisms of disease". Clinical Medicine & Research 1 (4): 291–300. doi:10.3121/cmr.1.4.291. PMID 15931322. PMC 1069058. http://www.clinmedres.org/cgi/pmidlookup?view=long&pmid=15931322. Retrieved 2009-06-19.
- ^ Nicod J, Dick B, Frey FJ, Ferrari P (February 2004). "Mutation analysis of CYP11B1 and CYP11B2 in patients with increased 18-hydroxycortisol production". Molecular and Cellular Endocrinology 214 (1-2): 167–74. doi:10.1016/j.mce.2003.10.056. PMID 15062555. http://linkinghub.elsevier.com/retrieve/pii/S030372070300443X. Retrieved 2009-06-19.
- ^ McMahon GT, Dluhy RG (2004). "Glucocorticoid-remediable aldosteronism". Cardiology in Review 12 (1): 44–8. doi:10.1097/01.crd.0000096417.42861.ce. PMID 14667264. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1061-5377&volume=12&issue=1&spage=44. Retrieved 2009-06-19.
- ^ Ziaja J, Cholewa K, Mazurek U, Cierpka L (2008). "[Molecular basics of aldosterone and cortisol synthesis in normal adrenals and adrenocortical adenomas]" (in Polish). Endokrynologia Polska 59 (4): 330–9. PMID 18777504.
- ^ Astegiano M, Bresso F, Demarchi B, et al. (March 2005). "Association between Crohn's disease and Conn's syndrome. A report of two cases". Panminerva Medica 47 (1): 61–4. PMID 15985978.
- ^ Pereira RM, Michalkiewicz E, Sandrini F, et al. (October 2004). "[Childhood adrenocortical tumors"] (in Portuguese). Arquivos Brasileiros De Endocrinologia E Metabologia 48 (5): 651–8. doi:/S0004-27302004000500010 (inactive 2009-10-19). PMID 15761535. http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302004000500010&lng=en&nrm=iso&tlng=en. Retrieved 2009-06-19.
- ^ Kievit J, Haak HR (March 2000). "Diagnosis and treatment of adrenal incidentaloma. A cost-effectiveness analysis". Endocrinology and Metabolism Clinics of North America 29 (1): 69–90, viii–ix. doi:10.1016/S0889-8529(05)70117-1. PMID 10732265.
- ^ Kumar, Abbas, Fausto. Robbins and Cotran Pathologic Basis of Disease, 7th ed. Elsevier-Saunders; New York, 2005.
- ^ Yudofsky, Stuart C.; Robert E. Hales (2007). The American Psychiatric Publishing Textbook of Neuropsychiatry and Behavioral Neurosciences (5th ed.). American Psychiatric Pub, Inc.. ISBN 1585622397.
- ^ Ecder T, Schrier RW (April 2009). "Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease". Nature Reviews. Nephrology 5 (4): 221–8. doi:10.1038/nrneph.2009.13. PMID 19322187.
- ^ Gross P (May 2008). "Polycystic kidney disease: will it become treatable?". Polskie Archiwum Medycyny Wewnȩtrznej 118 (5): 298–301. PMID 18619180. http://tip.org.pl/pamw/issue/search.html?lang=en&search=18619180. Retrieved 2009-06-19.
- ^ Masoumi A, Reed-Gitomer B, Kelleher C, Schrier RW (2007). "Potential pharmacological interventions in polycystic kidney disease". Drugs 67 (17): 2495–510. doi:10.2165/00003495-200767170-00004. PMID 18034588.
- ^ Chapman AB (May 2007). "Autosomal dominant polycystic kidney disease: time for a change?". Journal of the American Society of Nephrology : JASN 18 (5): 1399–407. doi:10.1681/ASN.2007020155. PMID 17429048. http://jasn.asnjournals.org/cgi/pmidlookup?view=long&pmid=17429048. Retrieved 2009-06-19.
- ^ Chapman AB (July 2008). "Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies". Clinical Journal of the American Society of Nephrology : CJASN 3 (4): 1197–204. doi:10.2215/CJN.00060108. PMID 18579674. http://cjasn.asnjournals.org/cgi/pmidlookup?view=long&pmid=18579674. Retrieved 2009-06-19.
- ^ Berthoux FC, Mohey H, Afiani A (January 2008). "Natural history of primary IgA nephropathy". Seminars in Nephrology 28 (1): 4–9. doi:10.1016/j.semnephrol.2007.10.001. PMID 18222341. http://journals.elsevierhealth.com/retrieve/pii/S0270-9295(07)00139-8. Retrieved 2009-06-19.
- ^ D'Cruz D (February 2009). "Renal manifestations of the antiphospholipid syndrome". Current Rheumatology Reports 11 (1): 52–60. doi:10.1007/s11926-009-0008-2. PMID 19171112.
- ^ Licht C, Fremeaux-Bacchi V (February 2009). "Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis". Thrombosis and Haemostasis 101 (2): 271–8. PMID 19190809. http://www.schattauer.de/index.php?id=1268&pii=th09020271&no_cache=1. Retrieved 2009-06-19.
- ^ Textor SC (May 2009). "Current approaches to renovascular hypertension". The Medical Clinics of North America 93 (3): 717–32, Table of Contents. doi:10.1016/j.mcna.2009.02.012. PMID 19427501. PMC 2752469. http://journals.elsevierhealth.com/retrieve/pii/S0025-7125(09)00028-5. Retrieved 2009-06-19.
- ^ Voiculescu A, Rump LC (January 2009). "[Hypertension in patients with renal artery stenosis]" (in German). Der Internist 50 (1): 42–50. doi:10.1007/s00108-008-2198-5. PMID 19096816.
- ^ Kendrick J, Chonchol M (October 2008). "Renal artery stenosis and chronic ischemic nephropathy: epidemiology and diagnosis". Advances in Chronic Kidney Disease 15 (4): 355–62. doi:10.1053/j.ackd.2008.07.004. PMID 18805381. http://linkinghub.elsevier.com/retrieve/pii/S1548-5595(08)00107-9. Retrieved 2009-06-19.
- ^ Méndez GP, Klock C, Nosé V (December 2008). "Juxtaglomerular Cell Tumor of the Kidney: Case Report and Differential Diagnosis With Emphasis on Pathologic and Cytopathologic Features". Int. J. Surg. Pathol.. doi:10.1177/1066896908329413. PMID 19098017. http://ijs.sagepub.com/cgi/pmidlookup?view=long&pmid=19098017.
- ^ Kassim TA, Clarke DD, Mai VQ, Clyde PW, Mohamed Shakir KM (December 2008). "Catecholamine-induced cardiomyopathy". Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 14 (9): 1137–49. PMID 19158054. http://aace.metapress.com/openurl.asp?genre=article&issn=1530-891X&volume=14&issue=9&spage=1137. Retrieved 2009-06-19.
- ^ Simone Rossi, ed (2006). Australian medicines handbook 2006. Adelaide: Australian Medicines Handbook Pty Ltd. ISBN 0-9757919-2-3.
- ^ a b c d White WB (May 2009). "Defining the problem of treating the patient with hypertension and arthritis pain". The American Journal of Medicine 122 (5 Suppl): S3–9. doi:10.1016/j.amjmed.2009.03.002. PMID 19393824. http://linkinghub.elsevier.com/retrieve/pii/S0002-9343(09)00206-X. Retrieved 2009-06-18.
- ^ Mackenzie IS, Rutherford D, MacDonald TM (2008). "Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis". Arthritis Research & Therapy 10 Suppl 2: S3. doi:10.1186/ar2464. PMID 19007428. PMC 2582806. http://arthritis-research.com/content/10%20Suppl%202//S3. Retrieved 2009-06-18.
- ^ Berenbaum F (2008). "New horizons and perspectives in the treatment of osteoarthritis". Arthritis Research & Therapy 10 Suppl 2: S1. doi:10.1186/ar2462. PMID 19007426. PMC 2582808. http://arthritis-research.com/content/10%20Suppl%202//S1. Retrieved 2009-06-18.
- ^ Akinbamowo AO, Salzberg DJ, Weir MR (October 2008). "Renal consequences of prostaglandin inhibition in heart failure". Heart Failure Clinics 4 (4): 505–10. doi:10.1016/j.hfc.2008.03.002. PMID 18760760. http://linkinghub.elsevier.com/retrieve/pii/S1551-7136(08)00054-8. Retrieved 2009-06-18.
- ^ Lowenstein J (January 1980). "Drugs five years later: clonidine". Annals of Internal Medicine 92 (1): 74–7. PMID 6101302.
- ^ Robertson JI (January 1997). "Risk factors and drugs in the treatment of hypertension". Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension 15 (1): S43–6. PMID 9050985.
- ^ Schachter M (August 1999). "Moxonidine: a review of safety and tolerability after seven years of clinical experience". Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension 17 (3): S37–9. PMID 10489097.
- ^ Schäfer SG, Kaan EC, Christen MO, Löw-Kröger A, Mest HJ, Molderings GJ (July 1995). "Why imidazoline receptor modulator in the treatment of hypertension?". Annals of the New York Academy of Sciences 763: 659–72. doi:10.1111/j.1749-6632.1995.tb32460.x. PMID 7677385. http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0077-8923&date=1995&volume=763&spage=659. Retrieved 2009-06-18.
- ^ Larsen R, Kleinschmidt S (April 1995). "[Controlled hypotension]" (in German). Der Anaesthesist 44 (4): 291–308. PMID 7785759.
- ^ Scholtysik G (March 1986). "Animal pharmacology of guanfacine". The American Journal of Cardiology 57 (9): 13E–17E. doi:10.1016/0002-9149(86)90717-4. PMID 3006469.
- ^ a b Myers MG (January 1977). "New drugs in hypertension". Canadian Medical Association Journal 116 (2): 173–6. PMID 343894.
- ^ van Zwieten PA, Thoolen MJ, Timmermans PB (1984). "The hypotensive activity and side effects of methyldopa, clonidine, and guanfacine". Hypertension 6 (5 Pt 2): II28–33. PMID 6094346.
- ^ Kang A, Struben H (November 2008). "[Pre-eclampsia screening in first and second trimester]" (in German). Therapeutische Umschau. Revue Thérapeutique 65 (11): 663–6. doi:10.1024/0040-59126.96.36.1993. PMID 18979429.
- ^ Marik PE (March 2009). "Hypertensive disorders of pregnancy". Postgraduate Medicine 121 (2): 69–76. doi:10.3810/pgm.2009.03.1978. PMID 19332964. http://www.postgradmed.com/index.php?art=pgm_03_2009?article=1978. Retrieved 2009-06-18.
- ^ Mounier-Vehier C, Delsart P (April 2009). "[Pregnancy-related hypertension: a cardiovascular risk situation"] (in French). Presse Médicale (Paris, France : 1983) 38 (4): 600–8. doi:10.1016/j.lpm.2008.11.018. PMID 19250798. http://www.masson.fr/masson/S0755-4982(09)00045-1. Retrieved 2009-06-18.
- ^ Pack AI, Gislason T (2009). "Obstructive sleep apnea and cardiovascular disease: a perspective and future directions". Progress in Cardiovascular Diseases 51 (5): 434–51. doi:10.1016/j.pcad.2009.01.002. PMID 19249449. http://linkinghub.elsevier.com/retrieve/pii/S0033-0620(09)00003-6. Retrieved 2009-06-20.
- ^ Silverberg DS, Iaina A and Oksenberg A (January 2002). "Treating Obstructive Sleep Apnea Improves Essential Hypertension and Quality of Life". American Family Physician 65 (2): 229–36. PMID 11820487. http://www.aafp.org/afp/20020115/229.html.
- ^ Tomimoto H, Ihara M, Takahashi R, Fukuyama H (November 2008). "[Functional imaging in Binswanger's disease]" (in Japanese). Rinshō Shinkeigaku = Clinical Neurology 48 (11): 947–50. PMID 19198127.
- ^ Arsenic trioxide drugs dot com
- ^ atsdr-medical management guidelines for arsenic trioxide
- ^ Arsenic Author: Frances M Dyro, MD, Chief of the Neuromuscular Section, Associate Professor, Department of Neurology, New York Medical College, Westchester Medical Center
- ^ Can Med Assoc J. 1928 March; 18(3): 281–285. PMCID: PMC1710082 The Use of Sodium Chloride, Potassium Chloride, Sodium Bromide, and Potassium Bromide in Cases of Arterial Hypertension which are Amenable to Potassium Chloride W. L. T. Addison
- ^ Pimenta E, Oparil S (2009). "Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors". Vascular Health and Risk Management 5 (1): 453–63. PMID 19475781.
- ^ a b Reisin E, Jack AV (May 2009). "Obesity and hypertension: mechanisms, cardio-renal consequences, and therapeutic approaches". The Medical Clinics of North America 93 (3): 733–51. doi:10.1016/j.mcna.2009.02.010. PMID 19427502. http://journals.elsevierhealth.com/retrieve/pii/S0025-7125(09)00025-X. Retrieved 2009-06-30.
- ^ a b c Sowers JR, Whaley-Connell A, Epstein M (June 2009). "Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension". Annals of Internal Medicine 150 (11): 776–83. PMID 19487712. PMC 2824330. http://www.annals.org/cgi/pmidlookup?view=long&pmid=19487712. Retrieved 2009-06-30.
- ^ McConnaughey MM, McConnaughey JS, Ingenito AJ (June 1999). "Practical considerations of the pharmacology of angiotensin receptor blockers". Journal of Clinical Pharmacology 39 (6): 547–59. doi:10.1177/00912709922008155. PMID 10354958. http://jcp.sagepub.com/cgi/pmidlookup?view=long&pmid=10354958. Retrieved 2009-06-30.
- ^ Manrique C, Lastra G, Gardner M, Sowers JR (May 2009). "The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress". The Medical Clinics of North America 93 (3): 569–82. doi:10.1016/j.mcna.2009.02.014. PMID 19427492. PMC 2828938. http://journals.elsevierhealth.com/retrieve/pii/S0025-7125(09)00027-3. Retrieved 2009-06-30.
- ^ Nistala R, Wei Y, Sowers JR, Whaley-Connell A (March 2009). "Renin-angiotensin-aldosterone system-mediated redox effects in chronic kidney disease". Translational Research : the Journal of Laboratory and Clinical Medicine 153 (3): 102–13. doi:10.1016/j.trsl.2008.12.008. PMID 19218092. PMC 2680726. http://linkinghub.elsevier.com/retrieve/pii/S1931-5244(08)00361-7. Retrieved 2009-06-30.
- ^ Takahashi H (August 2008). "[Sympathetic hyperactivity in hypertension]" (in Japanese). Nippon Rinsho. Japanese Journal of Clinical Medicine 66 (8): 1495–502. PMID 18700548.
- ^ Esler M (June 2000). "The sympathetic system and hypertension". American Journal of Hypertension 13 (6 Pt 2): 99S–105S. doi:10.1016/S0895-7061(00)00225-9. PMID 10921528.
- ^ Mark AL (December 1996). "The sympathetic nervous system in hypertension: a potential long-term regulator of arterial pressure". Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension 14 (5): S159–65. PMID 9120673.
- ^ Somers VK, Anderson EA, Mark AL (January 1993). "Sympathetic neural mechanisms in human hypertension". Current Opinion in Nephrology and Hypertension 2 (1): 96–105. PMID 7922174.
- ^ Sagnella GA, Swift PA (June 2006). "The Renal Epithelial Sodium Channel: Genetic Heterogeneity and Implications for the Treatment of High Blood Pressure". Current Pharmaceutical Design 12 (14): 2221–2234. doi:10.2174/138161206777585157. PMID 16787251.
- ^ Johnson JA, Turner ST (June 2005). "Hypertension pharmacogenomics: current status and future directions". Current Opinion in Molecular Therapy 7 (3): 218–225. PMID 15977418.
- ^ Hideo Izawa; Yoshiji Yamada et al. (May 2003). "Prediction of Genetic Risk for Hypertension". Hypertension 41 (5): 1035–1040. doi:10.1161/01.HYP.0000065618.56368.24. PMID 12654703. http://hyper.ahajournals.org/cgi/content/short/01.HYP.0000065618.56368.24v1.
- ^ Reeves R (1995). "The rational clinical examination. Does this patient have hypertension? How to measure blood pressure". JAMA 273 (15): 1211–8. doi:10.1001/jama.273.15.1211. PMID 7707630.
- ^ White W, Lund-Johansen P, Omvik P (1990). "Assessment of four ambulatory blood pressure monitors and measurements by clinicians versus intraarterial blood pressure at rest and during exercise". Am J Cardiol 65 (1): 60–6. doi:10.1016/0002-9149(90)90026-W. PMID 2294682.
- ^ Kim J, Bosworth H, Voils C, Olsen M, Dudley T, Gribbin M, Adams M, Oddone E (2005). "How well do clinic-based blood pressure measurements agree with the mercury standard?". J Gen Intern Med 20 (7): 647–9. doi:10.1007/s11606-005-0112-6. PMID 16050862.
- ^ Blood Pressure Monitoring. "Blood Pressure Monitoring". http://www.blood-pressure-monitoring.org.
- ^ The American Heart Association. "Home Monitoring of High Blood Pressure". http://www.americanheart.org/presenter.jhtml?identifier=576.
- ^ Smulyan H, Safar ME (February 2000). "The diastolic blood pressure in systolic hypertension". Annals of Internal Medicine 132 (3): 233–7. PMID 10651605.
- ^ Padwal RS, Hemmelgarn BR, Khan NA, et al. (May 2009). "The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1--blood pressure measurement, diagnosis and assessment of risk". The Canadian Journal of Cardiology 25 (5): 279–86. PMID 19417858.
- ^ a b Mulatero P, Bertello C, Verhovez A, et al. (June 2009). "Differential diagnosis of primary aldosteronism subtypes". Current Hypertension Reports 11 (3): 217–23. doi:10.1007/s11906-009-0038-1. PMID 19442332.
- ^ Padwal RJ, Hemmelgarn BR, Khan NA, et al. (June 2008). "The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of risk". The Canadian Journal of Cardiology 24 (6): 455–63. PMID 18548142.
- ^ Padwal RS, Hemmelgarn BR, McAlister FA, et al. (May 2007). "The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk". The Canadian Journal of Cardiology 23 (7): 529–38. PMID 17534459.
- ^ Hemmelgarn BR, McAlister FA, Grover S, et al. (May 2006). "The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk". The Canadian Journal of Cardiology 22 (7): 573–81. PMID 16755312.
- ^ Hemmelgarn BR, McAllister FA, Myers MG, et al. (June 2005). "The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk". The Canadian Journal of Cardiology 21 (8): 645–56. PMID 16003448.
- ^ Elley CR, Arroll B (2002). "Review: aerobic exercise reduces systolic and diastolic blood pressure in adults". ACP J. Club 137 (3): 109. PMID 12418849. http://www.acpjc.org/Content/137/3/Issue/ACPJC-2002-137-3-109.htm.
- ^ "Is Low Intensity Exercise A Superior Blood Pressure Reducer Than High Intensity Exercise?". Hypertension Library. http://www.hypertensionlibrary.com/is-low-intensity-exercise-a-superior-blood-pressure-reducer-than-high-intensity-exercise/. Retrieved 2009-02-01.
- ^ Klaus D, Böhm M, Halle M, et al. (May 2009). "[Restriction of salt intake in the whole population promises great long-term benefits"] (in German). Deutsche Medizinische Wochenschrift (1946) 134 Suppl 3: S108–18. doi:10.1055/s-0029-1222573. PMID 19418415. http://www.thieme-connect.com/DOI/DOI?10.1055/s-0029-1222573. Retrieved 2009-06-02.
- ^ Appel LJ, Moore TJ, Obarzanek E et al. (April 1997). "A Clinical Trial of the Effects of Dietary Patterns on Blood Pressure". New England Journal of Medicine 336 (16): 1117–24. doi:10.1056/NEJM199704173361601. PMID 9099655. http://content.nejm.org/cgi/content/full/336/16/1117.
- ^ Can Med Assoc J. 1928 March; 18(3): 281–285.PMCID: PMC1710082 The Use of Sodium Chloride, Potassium Chloride, Sodium Bromide, and Potassium Bromide in Cases of Arterial Hypertension which are Amenable to Potassium Chloride W. L. T. Addison
- ^ Benson, Herbert, M.D., The Relaxation Response, New York: Morrow, 1975. ISBN 0688029558
- ^ Mayo Clinic - Biofeedback
- ^ "Device-Guided Paced Breathing Lowers Blood Pressure, Blood Pressure". Press release. 2006-05-16. http://www.emaxhealth.com/106/5912.html. Retrieved 2009-07-03.
- ^ Elliott WJ, Izzo JL (2006). "Device-guided breathing to lower blood pressure: case report and clinical overview". MedGenMed 8 (3): 23. PMID 17406163. PMC 1781326. http://www.medscape.com/viewarticle/539099.
- ^ Nakao M, Yano E, Nomura S, Kuboki T (January 2003). "Blood pressure-lowering effects of biofeedback treatment in hypertension: a meta-analysis of randomized controlled trials" (). Hypertens. Res. 26 (1): 37–46. doi:10.1291/hypres.26.37. PMID 12661911. http://joi.jlc.jst.go.jp/JST.JSTAGE/hypres/26.37?from=PubMed.
- ^ Blumenthal JA, Babyak MA, Hinderliter A, et al. (January 2010). "Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study". Arch. Intern. Med. 170 (2): 126–35. doi:10.1001/archinternmed.2009.470. PMID 20101007.
- ^ a b "CCG73 Chronic kidney disease: quick reference guide" (PDF). National Institute for Health and Clinical Excellence. 24 September 2008. http://www.nice.org.uk/nicemedia/pdf/CG015adultsquickrefguide.pdf. Retrieved 2009-03-04.
- ^ Soucek M (April 2009). "[Target values of blood pressure in patients with diabetes mellitus]" (in Czech). Vnitr̆ní Lékar̆ství 55 (4): 363–7. PMID 19449751.
- ^ a b "CG15 Type 1 diabetes in adults: quick reference guide" (PDF). National Institute for Health and Clinical Excellence. 21 July 2004. http://www.nice.org.uk/nicemedia/pdf/CG015adultsquickrefguide.pdf. Retrieved 2009-03-04.
- ^ "CG66 Diabetes - type 2 (update): quick reference guide" (PDF). National Institute for Health and Clinical Excellence. 28 May 2008. http://www.nice.org.uk/nicemedia/pdf/CG66T2DQRG.pdf. Retrieved 2009-03-04.
- ^ Shaw, Gina (2009-03-07). "Prehypertension: Early-stage High Blood Pressure". WebMD. http://www.webmd.com/content/article/73/88927.htm. Retrieved 2009-07-03.
- ^ Kragten JA, Dunselman PHJM. Nifedipine gastrointestinal therapeutic system (GITS) in the treatment of coronary heart disease and hypertension. Expert Rev Cardiovasc Ther 5 (2007):643-653. FULL TEXT!
- ^ Piller LB, Davis BR, Cutler JA, et al. (November 2002). "Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone". Curr Control Trials Cardiovasc Med 3 (1): 10. doi:10.1186/1468-6708-3-10. PMID 12459039.
- ^ Mayor S (2006). "NICE removes beta blockers as first line treatment for hypertension". BMJ 333 (7557): 8. doi:10.1136/bmj.333.7557.8-a. PMID 16809680. PMC 1488775. http://www.bmj.com/cgi/content/full/333/7557/8-a.
- ^ Presentation on Direct Renin Inhibitors as Antihypertensive Drugs
- ^ Widimský J (February 2009). "[The combination of an ACE inhibitor and a calcium channel blocker is an optimal combination for the treatment of hypertension]" (in Czech). Vnitr̆ní Lékar̆ství 55 (2): 123–30. PMID 19348394.
- ^ ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (December 18 2002). "Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)". JAMA 288 (23): 2981–97. doi:10.1001/jama.288.23.2981. PMID 12479763. http://jama.ama-assn.org/cgi/content/full/288/23/2981.
- ^ Wing LM, Reid CM, Ryan P et al. (February 13 2003). "A comparison of outcomes with angiotensin-converting—enzyme inhibitors and diuretics for hypertension in the elderly". NEJM 348 (7): 583–92. doi:10.1056/NEJMoa021716. PMID 12584366. http://content.nejm.org/cgi/content/abstract/348/7/583.
- ^ Lewis PJ, Kohner EM, Petrie A, Dollery CT (1976). "Deterioration of glucose tolerance in hypertensive patients on prolonged diuretic treatment". Lancet 307 (7959): 564–566. doi:10.1016/S0140-6736(76)90359-7. PMID 55840.
- ^ Murphy MB, Lewis PJ, Kohner E, Schumer B, Dollery CT (1982). "Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up". Lancet 320 (8311): 1293–1295. doi:10.1016/S0140-6736(82)91506-9. PMID 6128594.
- ^ Messerli FH, Williams B, Ritz E (2007). "Essential hypertension". Lancet 370 (9587): 591–603. doi:10.1016/S0140-6736(07)61299-9. PMID 17707755.
- ^ "Section 11. Cardiovascular Disorders - Chapter 85. Hypertension". Merck Manual of Geriatrics. July 2005. http://www.merck.com/mkgr/mmg/sec11/ch85/ch85a.jsp.
- ^ Williams B (November 2003). "Treatment of hypertension in the UK: simple as ABCD?". J R Soc Med 96 (11): 521–2. doi:10.1258/jrsm.96.11.521. PMID 14594956. PMC 539621. http://www.jrsm.org/cgi/pmidlookup?view=long&pmid=14594956.
- ^ Insull W (January 2009). "The pathology of atherosclerosis: plaque development and plaque responses to medical treatment". The American Journal of Medicine 122 (1 Suppl): S3–S14. doi:10.1016/j.amjmed.2008.10.013. PMID 19110086. http://linkinghub.elsevier.com/retrieve/pii/S0002-9343(08)01017-6. Retrieved 2009-06-20.
- ^ Liapis CD, Avgerinos ED, Kadoglou NP, Kakisis JD (May 2009). "What a vascular surgeon should know and do about atherosclerotic risk factors". [[Journal of Vascular Surgery : Official Publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, North American Chapter]] 49 (5): 1348–54. doi:10.1016/j.jvs.2008.12.046. PMID 19394559. http://linkinghub.elsevier.com/retrieve/pii/S0741-5214(08)02276-3. Retrieved 2009-06-20.
- ^ Riccioni G (2009). "The effect of antihypertensive drugs on carotid intima media thickness: an up-to-date review". Current Medicinal Chemistry 16 (8): 988–96. doi:10.2174/092986709787581923. PMID 19275607. http://www.bentham-direct.org/pages/content.php?CMC/2009/00000016/00000008/0006C.SGM. Retrieved 2009-06-20.
- ^ Safar ME, Jankowski P (February 2009). "Central blood pressure and hypertension: role in cardiovascular risk assessment". Clinical Science (London, England : 1979) 116 (4): 273–82. doi:10.1042/CS20080072. PMID 19138169. http://www.clinsci.org/cs/116/0273/cs1160273.htm. Retrieved 2009-06-20.
- ^ Werner CM, Böhm M (June 2008). "The therapeutic role of RAS blockade in chronic heart failure". Therapeutic Advances in Cardiovascular Disease 2 (3): 167–77. doi:10.1177/1753944708091777. PMID 19124420. http://tak.sagepub.com/cgi/pmidlookup?view=long&pmid=19124420. Retrieved 2009-06-20.
- ^ Gaddam KK, Verma A, Thompson M, Amin R, Ventura H (May 2009). "Hypertension and cardiac failure in its various forms". The Medical Clinics of North America 93 (3): 665–80. doi:10.1016/j.mcna.2009.02.005. PMID 19427498. http://journals.elsevierhealth.com/retrieve/pii/S0025-7125(09)00020-0. Retrieved 2009-06-20.
- ^ Agabiti-Rosei E (September 2008). "From macro- to microcirculation: benefits in hypertension and diabetes". Journal of Hypertension 26 Suppl 3: S15–21. doi:10.1097/01.hjh.0000334602.71005.52. PMID 18815511. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0263-6352&volume=26&issue=&spage=S15. Retrieved 2009-06-20.
- ^ a b c Agabiti-Rosei E (September 2008). "From macro- to microcirculation: benefits in hypertension and diabetes". Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension 26 (3): S15–9. PMID 19363848.
- ^ Murphy BP, Stanton T, Dunn FG (May 2009). "Hypertension and myocardial ischemia". The Medical Clinics of North America 93 (3): 681–95. doi:10.1016/j.mcna.2009.02.003. PMID 19427499. http://journals.elsevierhealth.com/retrieve/pii/S0025-7125(09)00018-2. Retrieved 2009-06-20.
- ^ Tylicki L, Rutkowski B (February 2003). "[Hypertensive nephropathy: pathogenesis, diagnosis and treatment]" (in Polish). Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego 14 (80): 168–73. PMID 12728683.
- ^ Truong LD, Shen SS, Park MH, Krishnan B (February 2009). "Diagnosing nonneoplastic lesions in nephrectomy specimens". Archives of Pathology & Laboratory Medicine 133 (2): 189–200. PMID 19195963. http://journals.allenpress.com/jrnlserv/?request=get-abstract&issn=0003-9985&volume=133&page=189. Retrieved 2009-06-20.
- ^ Tracy RE, White S (February 2002). "A method for quantifying adrenocortical nodular hyperplasia at autopsy: some use of the method in illuminating hypertension and atherosclerosis". Annals of Diagnostic Pathology 6 (1): 20–9. doi:10.1053/adpa.2002.30606. PMID 11842376. http://linkinghub.elsevier.com/retrieve/pii/S1092913402249217. Retrieved 2009-06-20.
- ^ Singer DR, Kite A (June 2008). "Management of hypertension in peripheral arterial disease: does the choice of drugs matter?". European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery 35 (6): 701–8. doi:10.1016/j.ejvs.2008.01.007. PMID 18375152. http://linkinghub.elsevier.com/retrieve/pii/S1078-5884(08)00047-6. Retrieved 2009-06-20.
- ^ Aronow WS (August 2008). "Hypertension and the older diabetic". Clinics in Geriatric Medicine 24 (3): 489–501, vi–vii. doi:10.1016/j.cger.2008.03.001. PMID 18672184. http://journals.elsevierhealth.com/retrieve/pii/S0749-0690(08)00012-8. Retrieved 2009-06-20.
- ^ Gardner AW, Afaq A (2008). "Management of lower extremity peripheral arterial disease". Journal of Cardiopulmonary Rehabilitation and Prevention 28 (6): 349–57. doi:10.1097/HCR.0b013e31818c3b96 (inactive 2009-10-19). PMID 19008688. PMC 2743684. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1932-7501&volume=28&issue=6&spage=349. Retrieved 2009-06-20.
- ^ Novo S, Lunetta M, Evola S, Novo G (January 2009). "Role of ARBs in the blood hypertension therapy and prevention of cardiovascular events". Current Drug Targets 10 (1): 20–5. doi:10.2174/138945009787122897. PMID 19149532. http://www.bentham-direct.org/pages/content.php?CDT/2009/00000010/00000001/0003J.SGM. Retrieved 2009-06-20.
- ^ a b c Zeng C, Villar VA, Yu P, Zhou L, Jose PA (April 2009). "Reactive oxygen species and dopamine receptor function in essential hypertension". Clinical and Experimental Hypertension (New York, N.Y. : 1993) 31 (2): 156–78. doi:10.1080/10641960802621283. PMID 19330604. http://www.informaworld.com/openurl?genre=article&doi=10.1080/10641960802621283&magic=pubmed||1B69BA326FFE69C3F0A8F227DF8201D0. Retrieved 2009-06-20.
- ^ Varon J (October 2007). "Diagnosis and management of labile blood pressure during acute cerebrovascular accidents and other hypertensive crises". The American Journal of Emergency Medicine 25 (8): 949–59. doi:10.1016/j.ajem.2007.02.032. PMID 17920983. http://linkinghub.elsevier.com/retrieve/pii/S0735-6757(07)00174-X. Retrieved 2009-06-20.
- ^ Sare GM, Geeganage C, Bath PM (2009). "High blood pressure in acute ischaemic stroke--broadening therapeutic horizons". Cerebrovascular Diseases (Basel, Switzerland) 27 Suppl 1: 156–61. doi:10.1159/000200454. PMID 19342846. http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=000200454. Retrieved 2009-06-20.
- ^ Palm F, Urbanek C, Grau A (April 2009). "Infection, its treatment and the risk for stroke". Current Vascular Pharmacology 7 (2): 146–52. doi:10.2174/157016109787455707. PMID 19355997. http://www.bentham-direct.org/pages/content.php?CVP/2009/00000007/00000002/004AD.SGM. Retrieved 2009-06-20.
- ^ Tanahashi N (April 2009). "[Roles of angiotensin II receptor blockers in stroke prevention]" (in Japanese). Nippon Rinsho. Japanese Journal of Clinical Medicine 67 (4): 742–9. PMID 19348237.
- ^ a b Pedrinelli R, Dell'Omo G, Talini E, Canale ML, Di Bello V (February 2009). "Systemic hypertension and the right-sided cardiovascular system: a review of the available evidence". Journal of Cardiovascular Medicine (Hagerstown, Md.) 10 (2): 115–21. doi:10.2459/JCM.0b013e32831da941 (inactive 2009-10-19). PMID 19377378. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1558-2027&volume=10&issue=2&spage=115. Retrieved 2009-06-02.
- ^ Papadopoulos DP, Papademetriou V (February 2009). "Hypertrophic and Hypertensive Hypertrophic Cardiomyopathy: A True Association?". Angiology 61 (1): 92–9. doi:10.1177/0003319709331391. PMID 19240104. http://ang.sagepub.com/cgi/pmidlookup?view=long&pmid=19240104. Retrieved 2009-06-21.
- ^ Thiele S, Britz S, Landsiedel L, Wallaschofski H, Lohmann T (August 2008). "Short-term changes in hsCRP and NT-proBNP levels in hypertensive emergencies". Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones et Métabolisme 40 (8): 561–5. doi:10.1055/s-2008-1073152. PMID 18459085. http://www.thieme-connect.com/DOI/DOI?10.1055/s-2008-1073152. Retrieved 2009-06-21.
- ^ Martín Raymondi D, Díaz Dorronsoro I, Barba J, Díez J (September 2005). "[Characteristics of hypertensive cardiomyopathy in a population of hypertensive patients never treated"] (in Spanish; Castilian). Medicina Clínica 125 (9): 321–4. PMID 16185630. http://www.elsevier.es/revistas/0025-7753/125/321. Retrieved 2009-06-21.
- ^ Motz W (October 2004). "[Right ventricle in arterial hypertension]" (in German). Der Internist 45 (10): 1108–16. doi:10.1007/s00108-004-1273-9. PMID 15351931.
- ^ Steinmetz M, Nickenig G (April 2009). "[Cardiac sequelae of hypertension]" (in German). Der Internist 50 (4): 397–409. doi:10.1007/s00108-008-2289-3. PMID 19343394.
- ^ Goch A (October 2008). "[Blood pressure variability--clinical implications]" (in Polish). Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego 25 (148): 364–7. PMID 19145938.
- ^ Rodríguez NA, Zurutuza A (2008). "[Ophthalmological manifestations of arterial hypertension"] (in Spanish; Castilian). Anales Del Sistema Sanitario De Navarra 31 Suppl 3: 13–22. PMID 19169291. http://recyt.fecyt.es/index.php/ASSN/article/view/5209/4401. Retrieved 2009-06-21.
- ^ DellaCroce JT, Vitale AT (November 2008). "Hypertension and the eye". Current Opinion in Ophthalmology 19 (6): 493–8. doi:10.1097/ICU.0b013e3283129779. PMID 18854694. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1040-8738&volume=19&issue=6&spage=493. Retrieved 2009-06-21.
- ^ Barar A, Apatachioaie ID, Apatachioaie C, Marceanu L (2008). "[Hypertensive retinopathy--assessment]" (in Romanian). Oftalmologia (Bucharest, Romania : 1990) 52 (1): 3–12. PMID 18714483.
- ^ Uhler TA, Piltz-Seymour J (March 2008). "Optic disc hemorrhages in glaucoma and ocular hypertension: implications and recommendations". Current Opinion in Ophthalmology 19 (2): 89–94. doi:10.1097/ICU.0b013e3282f3e6bc. PMID 18301280. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1040-8738&volume=19&issue=2&spage=89. Retrieved 2009-06-21.
- ^ Wong TY, Wong T, Mitchell P (February 2007). "The eye in hypertension". Lancet 369 (9559): 425–35. doi:10.1016/S0140-6736(07)60198-6. PMID 17276782. http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(07)60198-6. Retrieved 2009-06-21.
- ^ Karpha M, Lip GV (August 2006). "The pathophysiology of target organ damage in hypertension". Minerva Cardioangiologica 54 (4): 417–29. PMID 17016413.
- ^ Nadar SK, Tayebjee MH, Messerli F, Lip GY (2006). "Target organ damage in hypertension: pathophysiology and implications for drug therapy". Current Pharmaceutical Design 12 (13): 1581–92. doi:10.2174/138161206776843368. PMID 16729871. http://www.bentham-direct.org/pages/content.php?CPD/2006/00000012/00000013/0004B.SGM. Retrieved 2009-06-21.
- ^ Grosso A, Veglio F, Porta M, Grignolo FM, Wong TY (December 2005). "Hypertensive retinopathy revisited: some answers, more questions". The British Journal of Ophthalmology 89 (12): 1646–54. doi:10.1136/bjo.2005.072546. PMID 16299149. PMC 1772998. http://bjo.bmj.com/cgi/pmidlookup?view=long&pmid=16299149. Retrieved 2009-06-21.
- ^ Wong TY, McIntosh R (2005). "Hypertensive retinopathy signs as risk indicators of cardiovascular morbidity and mortality". British Medical Bulletin 73-74: 57–70. doi:10.1093/bmb/ldh050. PMID 16148191. http://bmb.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=16148191. Retrieved 2009-06-21.
- ^ Porta M, Grosso A, Veglio F (April 2005). "Hypertensive retinopathy: there's more than meets the eye". Journal of Hypertension 23 (4): 683–96. doi:10.1097/01.hjh.0000163131.77267.11. PMID 15775767. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0263-6352&volume=23&issue=4&spage=683. Retrieved 2009-06-21.
- ^ Wong TY, Mitchell P (November 2004). "Hypertensive retinopathy". The New England Journal of Medicine 351 (22): 2310–7. doi:10.1056/NEJMra032865. PMID 15564546. http://content.nejm.org/cgi/pmidlookup?view=short&pmid=15564546&promo=ONFLNS19. Retrieved 2009-06-21.
- ^ Yoshimoto H, Ganka Y (March 2004). "[Hypertensive retinopathy]" (in Japanese). Nippon Rinsho. Japanese Journal of Clinical Medicine 62 Suppl 3: 381–5. PMID 15171404.
- ^ Chatterjee S, Chattopadhyay S, Hope-Ross M, Lip PL, Chattopadhya S (October 2002). "Hypertension and the eye: changing perspectives". Journal of Human Hypertension 16 (10): 667–75. doi:10.1038/sj.jhh.1001472. PMID 12420190.
- ^ Wang G, Lai FM, Kwan BC, et al. (March 2009). "Podocyte loss in human hypertensive nephrosclerosis". American Journal of Hypertension 22 (3): 300–6. doi:10.1038/ajh.2008.360. PMID 19131934.
- ^ Lubomirova M, Djerassi R, Kiperova B, Boyanov M, Christov V (2007). "Renal Doppler ultrasound in patients with hypertension and metabolic syndrom". Medicinski Pregled 60 Suppl 2: 84–6. PMID 18928166.
- ^ a b Burt VL, Cutler JA, Higgins M, et al. (July 1995). "Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991". Hypertension 26 (1): 60–9. PMID 7607734. http://hyper.ahajournals.org/cgi/pmidlookup?view=long&pmid=7607734. Retrieved 2009-06-05.
- ^ Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J (2005). "Global burden of hypertension: analysis of worldwide data". Lancet 365 (9455): 217–23. doi:10.1016/S0140-6736(05)17741-1. PMID 15652604. http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(05)17741-1. Retrieved 2009-06-22.
- ^ Vokonas PS, Kannel WB, Cupples LA (November 1988). "Epidemiology and risk of hypertension in the elderly: the Framingham Study". J Hypertens Suppl 6 (1): S3–9.
- ^ Burt VL, Whelton P, Roccella EJ, et al. (March 1995). "Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991". Hypertension 25 (3): 305–13. PMID 7875754. http://hyper.ahajournals.org/cgi/pmidlookup?view=long&pmid=7875754. Retrieved 2009-06-05.
- ^ Ostchega Y, Dillon CF, Hughes JP, Carroll M, Yoon S (July 2007). "Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004". J Am Geriatr Soc 55 (7): 1056–65. doi:10.1111/j.1532-5415.2007.01215.x. PMID 17608879. http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0002-8614&date=2007&volume=55&issue=7&spage=1056. Retrieved 2009-06-05.
- ^ Reaven GM, Lithell H, Landsberg L (February 1996). "Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system". The New England Journal of Medicine 334 (6): 374–81. doi:10.1056/NEJM199602083340607. PMID 8538710. http://content.nejm.org/cgi/pmidlookup?view=short&pmid=8538710&promo=ONFLNS19. Retrieved 2009-06-08.
- ^ Makaryus AN, Akhrass P, McFarlane SI (June 2009). "Treatment of hypertension in metabolic syndrome: implications of recent clinical trials". Curr. Diab. Rep. 9 (3): 229–37. doi:10.1007/s11892-009-0037-2. PMID 19490825.
- ^ a b Redon J, Cífková R, Narkiewicz K (April 2009). "Hypertension in the metabolic syndrome: summary of the new position statement of the European Society of Hypertension". Pol. Arch. Med. Wewn. 119 (4): 255–60. PMID 19413186. http://tip.org.pl/pamw/issue/search.html?lang=en&search=19413186. Retrieved 2009-06-07.
- ^ a b Falkner B (May 2009). "Hypertension in children and adolescents: epidemiology and natural history". Pediatr. Nephrol.. doi:10.1007/s00467-009-1200-3. PMID 19421783.
- ^ "Hypertension in Children and Adolescents". Hypertension in Children and Adolescents. American Academy of Family Physician. 2006. http://www.aafp.org/afp/20060501/1558.html. Retrieved 2007-07-24.
- ^ Dwivedi, Girish & Dwivedi, Shridhar (2007). History of Medicine: Sushruta – the Clinician – Teacher par Excellence. National Informatics Centre (Government of India).
- ^ edited by J.D. Swales. (1995). Manual of hypertension. Oxford: Blackwell Science. pp. xiii. ISBN 0-86542-861-1.
- ^ "What is Hypertension? - WrongDiagnosis.com". http://www.wrongdiagnosis.com/h/hypertension/basics.htm.
- ^ Alcocer L, Cueto L (June 2008). "Hypertension, a health economics perspective". Therapeutic Advances in Cardiovascular Disease 2 (3): 147–55. doi:10.1177/1753944708090572. PMID 19124418. http://tak.sagepub.com/cgi/pmidlookup?view=long&pmid=19124418. Retrieved 2009-06-20.
- ^ William J. Elliott (October 2003). "The Economic Impact of Hypertension". The Journal of Clinical Hypertension 5 (4): 3–13. doi:10.1111/j.1524-6175.2003.02463.x.
- ^ Theodoratou D, Maniadakis N, Fragoulakis V, Stamouli E (2009). "Analysis of published economic evaluations of angiotensin receptor blockers". Hellenic Journal of Cardiology : HJC = Hellēnikē Kardiologikē Epitheōrēsē 50 (2): 105–18. PMID 19329412. http://www.hellenicjcardiol.org/archive/full_text/2009/2/2009_2_105.pdf. Retrieved 2009-06-20.
- ^ Coca A (2008). "Economic benefits of treating high-risk hypertension with angiotensin II receptor antagonists (blockers)". Clinical Drug Investigation 28 (4): 211–20. doi:10.2165/00044011-200828040-00002. PMID 18345711.
- ^ Chockalingam A (May 2007). "Impact of World Hypertension Day". The Canadian Journal of Cardiology 23 (7): 517–9. PMID 17534457.
- ^ Chockalingam A (June 2008). "World Hypertension Day and global awareness". The Canadian Journal of Cardiology 24 (6): 441–4. PMID 18548140.
Hypertension at the Open Directory Project